Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Satellos Bioscience ( (TSE:MSCL) ) just unveiled an announcement.
Satellos Bioscience Inc., a clinical-stage biotech focused on therapies for degenerative muscle diseases such as Duchenne muscular dystrophy, develops SAT-3247, an oral small molecule aimed at restoring muscle stem cell signaling. The company’s shares are dual-listed on the Nasdaq Global Market under “MSLE” and on the Toronto Stock Exchange under “MSCL,” reflecting its cross-border capital markets presence.
On February 9, 2026, Satellos closed a US$57.2 million underwritten public offering of common shares and pre-funded warrants in Canada and the United States, including the full exercise of the underwriters’ option to purchase additional shares. The financing, which included a modest related-party subscription by director Franklin Berger, is expected to strengthen Satellos’ balance sheet and support advancement of SAT-3247 through later-stage clinical trials and other R&D programs, potentially bolstering its position in the muscle disease therapeutics space.
The most recent analyst rating on (TSE:MSCL) stock is a Hold with a C$16.00 price target. To see the full list of analyst forecasts on Satellos Bioscience stock, see the TSE:MSCL Stock Forecast page.
Spark’s Take on TSE:MSCL Stock
According to Spark, TipRanks’ AI Analyst, TSE:MSCL is a Neutral.
The score is held down primarily by weak financial performance (pre-revenue, large losses, and heavy cash burn with ongoing funding risk). Technicals are supportive due to a clear uptrend, but overbought signals temper that strength. Valuation is also constrained by negative earnings and no dividend support.
To see Spark’s full report on TSE:MSCL stock, click here.
More about Satellos Bioscience
Satellos Bioscience Inc. is a Toronto-based, clinical-stage biotechnology company focused on developing medicines to restore natural muscle repair and regeneration in degenerative muscle diseases. Its lead candidate, SAT-3247, is an orally administered small molecule targeting AAK1 and is in clinical development as a potential disease-modifying treatment for Duchenne muscular dystrophy, with additional muscle disease indications under evaluation.
Average Trading Volume: 30,689
Technical Sentiment Signal: Buy
Current Market Cap: C$248.1M
See more insights into MSCL stock on TipRanks’ Stock Analysis page.